ClinicalTrials.gg
Enrolling by invitationNCT07664189LOTTO-CRTUpdated Jul 23, 2026

LBBP + CSP Versus LBBP Alone for Cardiac Resynchronization Therapy

An interventional study of Left Bundle Branch Optimized CRT and Stimulation of the left bundle branch area (LBBAP) in Heart Failure Low Output, sponsored by Clinica Cardio VID. Enrolling by invitation at 1 site in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Clinica Cardio VID · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Heart Failure with a site in Colombia — 7 open to participants now, 9 under way, 5 of them phase 3. Heart Failure · Colombia.

Planned enrollment
33rd of 34
10 · median 3,388
Started
2026
with 1 other
No phase
9 of 39
2 open now
Registered
39th of 39
by date
Lead sponsor
1 of 39
Clinica Cardio VID

Among the 39 studies in Heart Failure with a site in Colombia, this one is the 33rd largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2026, is one of 9 with no phase, and was the 39th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

7 of the 39 studies in Heart Failure with a site in Colombia are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Colombia have not opened yet or have stopped. Only those recruiting at a site in Colombia →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Heart Failure with a site in Colombia, or all of them as a file.
02

Study summary

The purpose of this pilot clinical trial is to evaluate whether a novel cardiac resynchronization strategy, called LOT-CRT, is more effective than standard physiological pacing alone (LBBAP) in patients with heart failure.

This is a randomized, single-center, crossover pilot study involving 10 patients. All participants will receive a specialized pacemaker (CRT-P) with leads implanted in two specific areas: the Left Bundle Branch Area (LBBAP) and the Coronary Sinus (CS).

Because of the crossover design, each patient will serve as their own control, receiving two different pacing configurations in a random order: Active Phase (LOT-CRT): Simultaneous pacing of the left bundle branch and the coronary sinus. Control Phase (LBBAP alone): Pacing only the left bundle branch area. Each treatment phase will last 6 months, for a total follow-up of 12 months per patient.

By testing both strategies in the same patient, this study will help clinicians identify the most effective way to restore heart synchrony and improve clinical outcomes in patients with advanced heart failure and conduction delays.

Read the detailed description

This is a single-center, randomized, crossover pilot clinical trial. Each patient will serve as their own control. Following the successful implantation of a device capable of stimulating the LBBAP and the coronary sinus, participants will be randomly assigned to one of two treatment sequences:

Sequence A: LOT-CRT (LBBAP + CS) for 6 months, followed by LBBAP alone Sequence B: LBBAP alone for 6 months, followed by LOT-CRT Each treatment phase will last 6 months, followed by an end-point evaluation and a crossover. Since the hemodynamic effect of electrical stimulation is immediate, no washout period is required between phases.

This study was designed as an exploratory pilot study; therefore, no formal sample size calculation was performed. The number of patients enrolled is considered adequate to assess the feasibility of the procedure, the safety of the crossover design, and to identify preliminary signals of clinical and electrical efficacy.

03

Conditions studied

  • Heart Failure Low Output

Browse trials for

Keywords

  • Left Bundle Branch Optimized CRT,
  • Left Bundle Branch Area Pacing
  • left ventricular ejection fraction
  • quality of life
  • Heart failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Standard CRT-P indications according to ESC 2021 (EF ≤50%, QRS ≥130 ms, sinus rhythm or controlled AF)
  3. class II-IV
  4. Coronary venous anatomy suitable for placement of a coronary sinus electrode.
  5. Signed .
  6. Successful implantation of electrodes in the coronary sinus and in the left bundle branch area (LBBAP)

Exclusion criteria

Exclusion Criteria:

  1. Concomitant indication for implantation of an implantable cardioverter-defibrillator (ICD) or CRT-D
  2. Significant uncorrected valvular disease or scheduled or anticipated cardiac surgery during the study period.
  3. Anatomical or technical for lead implantation in the coronary sinus or for lead implantation in the coronary sinus (such as sinus stenosis, coronary sinus branches unsuitable for cannulation, inability to advance and/or stabilize the lead, among others)
  4. Persistent atrial fibrillation with uncontrolled rate
  5. Comorbidities that may limit to \<1 year
  6. Participation in another clinical trial that could confound the evaluation of results within the last 6 months.
  7. Pregnancy or inadequate
  8. In the researcher's opinion, the participant would not comply with the activities and visits outlined in the study protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
10 participants (estimated)

Study arms

  • Active comparator
    Sequence A

    LOT-CRT (LBBAP + CS) for 6 months, followed by LBBAP alone

    Device: Left Bundle Branch Optimized CRT · Device: Stimulation of the left bundle branch area (LBBAP)

  • Active comparator
    Sequence B

    LBBAP for 6 months only, followed by LOT-CRT

    Device: Left Bundle Branch Optimized CRT · Device: Stimulation of the left bundle branch area (LBBAP)

Interventions

  • DeviceLeft Bundle Branch Optimized CRT

    The CS lead will be implanted in a posterolateral or lateral vein using venography and standard IV delivery sheaths. Proper lead placement is confirmed by stable fixation, pacing capture, and absence of diaphragmatic pacing. The configuration for each phase of the study (LOT-CRT or LBBAP alone) will be assigned during randomization.

    Also known as: LOT-CRT, Left bundle branch block pacing + coronary sinus pacing, LBBAP + CS, LOT-CRT Strategy, Combined stimulation, Maximized electrical resynchronization

  • DeviceStimulation of the left bundle branch area (LBBAP)

    The LBBAP lead will be implanted via a transvenous approach using the C315His sheath, targeting the left bundle branch area in the right ventricular septum, ideally between the basal septum and the mid-septal region. Criteria for confirming successful LBBAP capture will include: * Evidence of narrowing of the stimulated QRS complex compared to baseline. * Right bundle branch block morphology on the ECG-stimulus-to-R-wave time in V6 \<80 ms (if available). * Low and stable pacing threshold (\<1.5 V @ 0.4 ms). * Unipolar impedance between 400-1500 ohms. The CS lead will be implanted in a posterolateral or lateral vein using venography and standard IV delivery sheaths. Proper lead placement is confirmed by stable fixation, pacing capture, and absence of diaphragmatic pacing.

    Also known as: Stimulation of the left branch only

06

What researchers measure

Primary outcomes

  1. Compare the effects of the LOT-CRT strategy versus left bundle branch block pacing (LBBAP) alone in each patient, comparing baseline to the end of the study FEVI, quality of life and functional class by NYHA.

    Investigators will evaluate the following parameters in each patient: Left ventricular ejection fraction (LVEF) by echocardiography and electrocardiogram; functional capacity (NYHA class) using the 6-minute walk test and symptoms reported by the patient; quality of life (MLHFQ) using the MLHFQ quality of life scale

    Time frame: 12 months

Secondary outcomes

  1. Change in end-systolic diameter

    Absolute (mm) and relative (%) change in LVESV between baseline and 6 months.

    Time frame: 12 months

  2. QRS Duration

    Absolute (ms) and relative (%) changes in the 12-lead ECG.

    Time frame: 12 months

  3. Change in end-diastolic diameter

    Absolute (mm) and relative (%) change in LVEDV between baseline and 6 months.

    Time frame: 12 months

  4. NT-proBNP

    Absolute (ng/mL) and relative (%) change in NT-proBNP from baseline to 6 months

    Time frame: 12 months

  5. Echocardiographic responder

    LVEF ≥10% elevation or LVESV ≥15% decreased

    Time frame: 12 months

  6. Echocardiographic super-responder

    LVEF ≥50% or LVESV ≥30% decrease

    Time frame: 12 months

  7. Composite Clinical Outcome

    Cardiovascular Death or Hospitalization for Heart Failure

    Time frame: 12 months

  8. Procedural parameters

    Thresholds, P- and R-waves, impedance of each electrode.

    Time frame: 12 months

  9. Procedure Time/Fluoroscopy

    Total procedure time in minutes/ total fluoroscopy time in minutes.

    Time frame: 12 months

07

Study locations

1 site
  • Clinica CardioVID
    Medellín, Antioquia 050036, Colombia
08

References and documents

Publications

  • Upadhyay GA, Jastrzebski M, Foley P, Chandrasekaran B, Whinnett Z, Schaller RD, Gardas R, Richardson T, Moskal P, Kudlik D, Stadler RW, Zimmerman P, Burrell J, Waxman R, Cornelussen RN, Lyne J, Herweg B, Vijayaraman P. Echocardiographic response from left bundle branch area pacing optimized cardiac resynchronization therapy (LOT-CRT) vs traditional CRT. Heart Rhythm. 2025 Oct;22(10):2616-2624. doi: 10.1016/j.hrthm.2025.04.026. Epub 2025 Apr 18. PubMed 40254116 ↗
  • Chen X, Li X, Bai Y, Wang J, Qin S, Bai J, Wang W, Liang Y, Chen H, Su Y, Ge J. Electrical Resynchronization and Clinical Outcomes During Long-Term Follow-Up in Intraventricular Conduction Delay Patients Applied Left Bundle Branch Pacing-Optimized Cardiac Resynchronization Therapy. Circ Arrhythm Electrophysiol. 2023 Sep;16(9):e011761. doi: 10.1161/CIRCEP.122.011761. Epub 2023 Aug 14. PubMed 37577815 ↗
  • Parale C, Bootla D, Jain A, Satheesh S, Anantharaj A, Ahmed AS, Sukumaran SK, Balaguru S, Selvaraj R. Comparison of electrocardiographic parameters between left bundle optimized cardiac resynchronization therapy (LOT-CRT) and left bundle branch pacing-cardiac resynchronization therapy (LBBP-CRT). Pacing Clin Electrophysiol. 2023 Aug;46(8):840-847. doi: 10.1111/pace.14793. Epub 2023 Jul 21. PubMed 37477545 ↗
  • Jastrzebski M, Foley P, Chandrasekaran B, Whinnett Z, Vijayaraman P, Upadhyay GA, Schaller RD, Gardas R, Richardson T, Kudlik D, Stadler RW, Zimmerman P, Burrell J, Waxman R, Cornelussen RN, Lyne J, Herweg B. Multicenter Hemodynamic Assessment of the LOT-CRT Strategy: When Does Combining Left Bundle Branch Pacing and Coronary Venous Pacing Enhance Resynchronization?: Primary Results of the CSPOT Study. Circ Arrhythm Electrophysiol. 2024 Nov;17(11):e013059. doi: 10.1161/CIRCEP.124.013059. Epub 2024 Oct 23. PubMed 39440428 ↗
  • Vijayaraman P. Left Bundle Branch Pacing Optimized Cardiac Resynchronization Therapy: A Novel Approach. JACC Clin Electrophysiol. 2021 Aug;7(8):1076-1078. doi: 10.1016/j.jacep.2021.04.005. Epub 2021 Jul 28. No abstract available. PubMed 34332867 ↗
  • Burri H, Jastrzebski M, Cano O, Curila K, de Pooter J, Huang W, Israel C, Joza J, Romero J, Vernooy K, Vijayaraman P, Whinnett Z, Zanon F. EHRA clinical consensus statement on conduction system pacing implantation: endorsed by the Asia Pacific Heart Rhythm Society (APHRS), Canadian Heart Rhythm Society (CHRS), and Latin American Heart Rhythm Society (LAHRS). Europace. 2023 Apr 15;25(4):1208-1236. doi: 10.1093/europace/euad043. PubMed 37061848 ↗
  • Glikson M, Burri H, Abdin A, Cano O, Curila K, De Pooter J, Diaz JC, Drossart I, Huang W, Israel CW, Jastrzebski M, Joza J, Karvonen J, Keene D, Leclercq C, Mullens W, Pujol-Lopez M, Rao A, Vernooy K, Vijayaraman P, Zanon F, Michowitz Y, Nielsen JC, Boersma L, Blomstrom-Lundqvist C, Kronborg MB, Chung MK, Tse HF, Khan HR, Leyva F, Rojel-Martinez U, Rucinski M, Varma N. European Society of Cardiology (ESC) clinical consensus statement on indications for conduction system pacing, with special contribution of the European Heart Rhythm Association of the ESC and endorsed by the Asia Pacific Heart Rhythm Society, the Canadian Heart Rhythm Society, the Heart Rhythm Society, and the Latin American Heart Rhythm Society. Europace. 2025 Mar 28;27(4):euaf050. doi: 10.1093/europace/euaf050. PubMed 40159278 ↗
  • Jastrzebski M, Moskal P, Huybrechts W, Curila K, Sreekumar P, Rademakers LM, Ponnusamy SS, Herweg B, Sharma PS, Bednarek A, Rajzer M, Vijayaraman P. Left bundle branch-optimized cardiac resynchronization therapy (LOT-CRT): Results from an international LBBAP collaborative study group. Heart Rhythm. 2022 Jan;19(1):13-21. doi: 10.1016/j.hrthm.2021.07.057. Epub 2021 Jul 30. PubMed 34339851 ↗
  • Su L, Wang S, Wu S, Xu L, Huang Z, Chen X, Zheng R, Jiang L, Ellenbogen KA, Whinnett ZI, Huang W. Long-Term Safety and Feasibility of Left Bundle Branch Pacing in a Large Single-Center Study. Circ Arrhythm Electrophysiol. 2021 Feb;14(2):e009261. doi: 10.1161/CIRCEP.120.009261. Epub 2021 Jan 9. PubMed 33426907 ↗
  • Chung MK, Patton KK, Lau CP, Dal Forno ARJ, Al-Khatib SM, Arora V, Birgersdotter-Green UM, Cha YM, Chung EH, Cronin EM, Curtis AB, Cygankiewicz I, Dandamudi G, Dubin AM, Ensch DP, Glotzer TV, Gold MR, Goldberger ZD, Gopinathannair R, Gorodeski EZ, Gutierrez A, Guzman JC, Huang W, Imrey PB, Indik JH, Karim S, Karpawich PP, Khaykin Y, Kiehl EL, Kron J, Kutyifa V, Link MS, Marine JE, Mullens W, Park SJ, Parkash R, Patete MF, Pathak RK, Perona CA, Rickard J, Schoenfeld MH, Seow SC, Shen WK, Shoda M, Singh JP, Slotwiner DJ, Sridhar ARM, Srivatsa UN, Stecker EC, Tanawuttiwat T, Tang WHW, Tapias CA, Tracy CM, Upadhyay GA, Varma N, Vernooy K, Vijayaraman P, Worsnick SA, Zareba W, Zeitler EP. 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm. 2023 Sep;20(9):e17-e91. doi: 10.1016/j.hrthm.2023.03.1538. Epub 2023 May 20. PubMed 37283271 ↗
  • Sieniewicz BJ, Gould J, Porter B, Sidhu BS, Teall T, Webb J, Carr-White G, Rinaldi CA. Understanding non-response to cardiac resynchronisation therapy: common problems and potential solutions. Heart Fail Rev. 2019 Jan;24(1):41-54. doi: 10.1007/s10741-018-9734-8. PubMed 30143910 ↗
  • Herweg B, Welter-Frost A, Vijayaraman P. The evolution of cardiac resynchronization therapy and an introduction to conduction system pacing: a conceptual review. Europace. 2021 Apr 6;23(4):496-510. doi: 10.1093/europace/euaa264. PubMed 33247913 ↗
  • Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, Barrabes JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS, Deharo JC, Delgado V, Diller GP, Israel CW, Keren A, Knops RE, Kotecha D, Leclercq C, Merkely B, Starck C, Thylen I, Tolosana JM; ESC Scientific Document Group. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021 Sep 14;42(35):3427-3520. doi: 10.1093/eurheartj/ehab364. No abstract available. PubMed 34455430 ↗

Individual participant data

Plan to share: Yes — Individual participant data, appropriately anonymized, that support the reported results will be made available to qualified researchers for the purposes of scientific research or meta-analysis. Requests must be addressed to the Principal Investigator and include a formal proposal. All requests will be subject to approval by the institutional ethics committee. As this is a study with a small sample size (10 patients), the protocol strictly enforces confidentiality; therefore, prior approval is always required to share these data. The data will be available from 6 months to 5 years following the publication of the main results.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: The data will be available from 6 months to 5 years following the publication of the main results.

Access criteria: Requests must be addressed to the Principal Investigator and include a formal proposal. All requests will be subject to approval by the institutional ethics committee.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 12 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 24, 2026
StartActual
Jun 9, 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07664189
Lead sponsor
Clinica Cardio VID
Responsible party
Sponsor
First posted
Jun 24, 2026
Start date
Jun 9, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jul 23, 2026

Study contacts

Juan F Agudelo, Electrophysiologist
principal investigator · Clinica CardioVID
Susana Rios, Medical Epidemiologist
study director · Clinica CardioVID

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion